Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ingevity's Current Accrued Expense for the quarter that ended in Jun. 2026 was MXN1,487 Mil.
Ingevity's quarterly Current Accrued Expense
increased
from Dec. 2025 (MXN2,973 Mil) to Mar. 2026 (MXN3,341 Mil) but then
declined
from Mar. 2026 (MXN3,341 Mil) to Jun. 2026 (MXN1,487 Mil).
Ingevity's annual Current Accrued Expense
increased
from Dec. 2023 (MXN1,181 Mil) to Dec. 2024 (MXN1,383 Mil) and
increased
from Dec. 2024 (MXN1,383 Mil) to Dec. 2025 (MXN2,973 Mil).
The historical data trend for Ingevity's Current Accrued Expense can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.
What does a Current Accrued Expense of MXN1,487 Mil mean?
Ingevity (MEX:NGVT) has a Current Accrued Expense of MXN1,487 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Ingevity and its competitors.
Is Ingevity's Current Accrued Expense too high?
Ingevity's current Current Accrued Expense is MXN1,487 Mil. Overall, Ingevity has a GF Score™ of 62/100, reflecting its overall financial health beyond just this single metric.
How does Ingevity's Current Accrued Expense compare to CC and KWR?
Ingevity's Current Accrued Expense of MXN1,487 Mil can be compared against companies in the Chemicals industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Chemicals company?
A good Current Accrued Expense depends on the Chemicals industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Ingevity and its competitors. Ingevity's current Current Accrued Expense is MXN1,487 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ingevity stock overvalued right now?
Ingevity (MEX:NGVT) has a current Current Accrued Expense of MXN1,487 Mil. The stock's GF Value™ is MXN866.37, compared to a current price of MXN1,430.00 — trading 65.1% above its estimated fair value. The current Current Accrued Expense is MXN1,487 Mil. Ingevity's overall GF Score™ is 62/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Ingevity (MEX:NGVT), the current Current Accrued Expense is MXN1,487 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Ingevity (MEX:NGVT) Overvalued in 2026?
Based on GuruFocus' analysis, Ingevity stock appears to be overvalued.
The current stock price of MXN1,430.00 is trading 65.1% above its estimated GF Value™ of MXN866.37.
Key valuation signals for MEX:NGVT:
Current Accrued Expense: MXN1,487 Mil
GF Value™: MXN866.37 vs. price of MXN1,430.00 (65.1% above fair value)
No single metric tells the full story. See the MEX:NGVT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Ingevity Corp is a chemical manufacturer based in the United States. It conducts its operations through three segments, namely Performance Chemicals, Advanced Polymer Technologies, and Performance Materials. The bulk of its revenue is generated by the Performance Chemicals segment which deals with the manufacture and sale of specialty chemicals that find their use in a range of processes such as asphalt paving, oil exploration and production, agrochemicals, adhesives, lubricants, and publication inks. The Performance Materials segment, on the other hand, focuses on automotive carbon products used in automobiles. The Advanced Polymer Technologies segment produces caprolactone and caprolactone-based specialty polymers. The company generates the majority of its revenue from North America.
62GF Score
Get the complete analysis for MEX:NGVT
Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:NGVT has been successfully added to your 
